Shares of Avacta Group Plc (OTCMKTS:AVCTF – Get Free Report) traded down 8.2% on Thursday . The stock traded as low as $0.7899 and last traded at $0.7899. 3,750 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 11,906 shares. The stock had previously closed at $0.86.
Avacta Group Trading Down 8.2%
The company’s fifty day simple moving average is $0.85 and its 200-day simple moving average is $0.86.
About Avacta Group
Avacta Group plc is a UK-based biotechnology company specializing in the discovery, development and commercialization of Affimer® biotherapeutics and diagnostic reagents. The company’s proprietary Affimer platform uses small, engineered protein scaffolds that can be tailored to bind specifically to target molecules, offering an alternative to traditional antibodies. Avacta operates two core divisions: Avacta Therapeutics, which focuses on novel treatments in oncology and immune-related diseases, and Avacta Analytical, which develops reagents and point-of-care diagnostic tests.
In its diagnostics business, Avacta has applied the Affimer technology to lateral flow assays, most notably for rapid detection of viral pathogens such as SARS-CoV-2.
Featured Stories
- Five stocks we like better than Avacta Group
- Free: The Crypto Summit That Could Change Your Life
- Think You Missed Silver? You’re Wrong. Here’s Why.
- Your Bank Account Is No Longer Safe
- When to buy gold (mathematically)
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.
